Compare BFRI & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRI | BGLC |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | Malaysia |
| Employees | 93 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.1M |
| IPO Year | N/A | 2019 |
| Metric | BFRI | BGLC |
|---|---|---|
| Price | $0.81 | $2.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 104.5K | 6.8K |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,510,646.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $19.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.23 |
| 52 Week High | $1.18 | $15.19 |
| Indicator | BFRI | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 48.41 |
| Support Level | $0.80 | $2.12 |
| Resistance Level | $0.89 | $2.73 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 23.76 | 60.73 |
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.